China Biologic Products Holdings Profit Margin

The latest profit margin for CBPO is 29.04% as of December 2020. That compares with 27.22% in the prior-year period — up 6.7% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside China Biologic Products Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBPO's profit margin moved from 27.22% to 29.04% — a 6.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in China Biologic Products Holdings's valuation or profitability profile.

Against Healthcare companies, CBPO currently prints 29.04% for profit margin, while the sector average sits near 13.89%. That is roughly 109.0% above the sector mean. Large gaps often invite a closer look at China Biologic Products Holdings's growth, margins, and balance sheet.

Profit Margin shows how effectively China Biologic Products Holdings converts resources into returns. At 29.04%, CBPO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 27.22% in the prior-year period — up 6.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CBPO's profit margin (29.04%), review year-over-year change from 27.22%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.